BIO-RAD LABORATORIES, INC. acquisition history.

Stilla Technologies is a commercial-stage life science company that develops and markets next-generation droplet digital PCR (Polymerase Chain Reaction) systems supporting a broad range of genetic and molecular testing applications. approximately $257.7 million purchase consideration ($166.5M cash to sellers, $47.6M cash paid to debtors on Stilla's behalf, $15.0M to escrow, plus $28.6M fair value of contingent consideration of up to $50.0M).

Why it was attractive

1. 01 Commercial-stage
2. 02 next-generation droplet digital PCR technology adjacent to Bio-Rad's existing ddPCR franchise

Capabilities acquired

droplet digital PCR systemsmultiplex digital PCRgenetic and molecular testing instrumentation

Stilla is a commercial-stage life science company that develops and markets next-generation droplet digital Polymerase Chain Reaction (PCR) systems, which supports a broad range of genetic and molecular testing applications.

Curiosity Diagnostics is a late-stage, pre-commercial platform company developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market. $137.1 million total consideration, including fair value of contingent consideration of up to $70.0 million payable on technological development and sales milestones.

Why it was attractive

1. 01 Differentiated late-stage molecular diagnostics platform complementing Bio-Rad's Clinical Diagnostics offerings

Capabilities acquired

sample-to-answer rapid PCR diagnosticsmolecular diagnostics platform

Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market.

Post-close · earnings-call commentary

Per FY2025 10-K: in December 2025 Bio-Rad discontinued development of the IPR&D asset associated with the Curiosity acquisition and recorded an impairment charge of $127.7 million.

Dropworks is a development-stage company focused on developing a digital PCR product. $125.5 million total consideration.

Why it was attractive

1. 01 Early-stage digital PCR technology expanding Bio-Rad's PCR roadmap

Capabilities acquired

digital PCR product development

Dropworks is a development stage company focused on developing a digital PCR product. The strategic rationale for the transaction was to address additional opportunities in the PCR market.

Post-close · earnings-call commentary

Per FY2025 10-K: in December 2025 Bio-Rad impaired the IPR&D asset associated with the 2021 Dropworks acquisition for $81.7 million, citing technology-completion delays and a revised revenue forecast.

Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. $99.3 million total consideration, including fair value of contingent consideration of up to $60.0 million payable on certain 2021-2022 net-revenue achievement.

Why it was attractive

1. 01 Single-cell isolation and analysis platform adjacent to Bio-Rad's Life Science franchise

Capabilities acquired

single-cell isolationsingle-cell detection and analysis instruments and consumables

Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings.

RainDance Technologies' foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research, enabling ultra-sensitive detection of genetic variations. approximately $72.7 million (cash payments at closing of $72.9 million; a separate $10.0 million cash payment for a preexisting condition was recorded in cost of goods sold).

Why it was attractive

1. 01 Foundational droplet-microfluidics IP strengthening Bio-Rad's droplet digital PCR position

Capabilities acquired

droplet-based biological reactionsultra-sensitive genetic-variation detectionliquid-biopsy genomic tools

RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets... These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.

GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and leverages droplet digital PCR technology. $50.4 million total consideration ($39.7 million cash at closing plus $10.7 million contingent consideration, potentially up to $70.0 million on development/regulatory and sales milestones).

Why it was attractive

1. 01 Droplet-based sequencing workflow complementary to Bio-Rad's droplet digital PCR leadership

Capabilities acquired

droplet-based DNA sequencing workflowclinical diagnostics sequencing

We believe that GnuBIO's innovative DNA workflow is well-suited for the clinical diagnostics sequencing market and will leverage our leadership role in the area of droplet digital PCR.

Post-close · earnings-call commentary

Per later 10-Ks: in 2016 Bio-Rad fully impaired GnuBIO-related goodwill of $13.5 million and in-process research and development of $46.4 million.

AbD Serotec, acquired from MorphoSys AG, brought a comprehensive catalog of research antibodies to Bio-Rad's Life Science business. $62.2 million total consideration (net of cash received of $7.3 million).

Why it was attractive

1. 01 Comprehensive antibody catalog expanding Bio-Rad's Life Science reagent portfolio

Capabilities acquired

research antibodies catalogantibody reagents

In January 2013, we acquired 100% of the outstanding shares of AbD Serotec, a division of MorphoSys AG, for total consideration of $62.2 million (net of cash received of $7.3 million).

QuantaLife developed droplet digital PCR technology that became the foundation of Bio-Rad's droplet digital PCR (ddPCR) systems. $179.4 million fair value of consideration ($150.3 million cash at closing, $5.0 million holdback, $24.1 million contingent consideration; contingent portion could reach $48 million on sales and development milestones).

Why it was attractive

1. 01 Pioneering droplet digital PCR platform that established Bio-Rad's ddPCR franchise

Capabilities acquired

droplet digital PCR (ddPCR) technology and systems

In October 2011, we acquired all the issued and outstanding stock of QuantaLife, Inc. The fair value of the consideration as of the acquisition date was $179.4 million, which comprised of $150.3 million paid in cash at the closing date, a $5.0 million holdback... and $24.1 million in contingent consideration.

DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening. Founded in 1977 and based in Switzerland, DiaMed had annual sales of approximately US $200 million to hospitals, clinical laboratories, and blood banks in more than 100 countries, with nearly 800 employees. approximately 477 million Swiss francs in cash for ~77.7% of shares (with a subsequent tender offer for the remaining ~12.7%).

Why it was attractive

1. 01 Complete blood typing and screening product line with a strong global reputation
2. 02 complementing Bio-Rad's diagnostics business

Capabilities acquired

blood typing reagents and instrumentsblood screeningimmunohematology

DiaMed has an outstanding reputation for quality products and customer care and we believe this portfolio of products will fit in well with Bio-Rad's existing diagnostics business.

In August 2012, Bio-Rad acquired from Propel Labs, Inc. a new cell sorting system. $5.0 million in cash at closing (plus contingent consideration recognized for the cell sorting system).

Capabilities acquired

cell sorting system / flow cytometry

In August 2012, we acquired from Propel Labs, Inc. a new cell sorting system that included $5.0 million in cash at the closing date.

In July 2012, Bio-Rad acquired all of the outstanding shares of DiaMed Benelux, extending its DiaMed blood-typing diagnostics franchise in the Benelux region. 4.6 million Euros (approximately $5.6 million) in cash.

Capabilities acquired

blood typing diagnostics distribution

In July 2012, we acquired all of the outstanding shares of DiaMed Benelux for 4.6 million Euros (approximately $5.6 million) in cash.